- Email: [email protected]
Comparison of the Radiotherapeutic Efficacy in Nsclc with Postoperative Mediastinal Lymph Nodes Recurrence and Stage Iii
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.89
Poster Session (Poster presentations categorized by each organ) P2
13
3
Hisao Imai1, Haruyasu Murakami1, Reiko Yoshino2, Akira Ono1, Hiroaki Akamatsu1, Tetsuhiko Taira1, Hirotsugu Kenmotsu1, Tateaki Naito1, Yoshio Tomizawa2, Toshiaki Takahashi1 1 Division of Thoracic Oncology, Shizuoka Cancer Center 2 Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital
abstracts
Background: Whether local treatment would be equally effective in non-small cell lung cancer patients with postoperative mediastinal lymph nodes recurrence (group A) and primary stage III disease (group B) remains unclear.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v94/2240536 by guest on 24 October 2019
COMPARISON OF THE RADIOTHERAPEUTIC EFFICACY IN NSCLC WITH POSTOPERATIVE MEDIASTINAL LYMPH NODES RECURRENCE AND STAGE III
Methods: Between 2002 and 2009, in a total of 190 non-small cell lung cancer patients with mediastinal lymph nodes metastases treated by radiotherapy alone or chemoradiotherapy, the baseline patient characteristics, responses to radiotherapy alone or chemoradiotherapy and survival were compared between group A (n = 33) and group B (n = 157). Results: Male was the predominant gender, accounting for 60.6% of patients in group A and 78.9% of patients in group B (P = 0.04). Performance status (PS) 0 was the predominant PS, accounting for 78.7% of patients in group A and 57.3% of patients in group B (P = 0.02). The response rates in group A and group B were 66.6 and 72.3%, respectively (P = 0.64). PFS was not significant in group A and group B (median, 15.0 versus 11.0 months; hazard ratio, 0.78; 95% CI, 0.51–1.20; P = 0.26). Meanwhile, OS was superior in group A than in group B (median, 67.0 versus 39.0 months; hazard ratio, 0.56; 95% CI, 0.29–0.97; P = 0.03). Among postoperative patients, PFS (median, 12.5 versus 19.0 months; hazard ratio, 1.50; 95% CI, 0.64–3.49; P = 0.34) and OS (median, 67.0 versus 60.0 months; hazard ratio, 1.22; 95% CI, 0.36–4.14; P = 0.74) were no significance in radiotherapy alone group and chemoradiotherapy group, respectively. Conclusions: Postoperative mediastinal lymph nodes recurrent non-small cell lung cancer showed distinctive features: OS was superior in patients with postoperative mediastinal lymph nodes recurrence than in those with primary stage III disease, although the two groups showed comparable responses and PFS.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P2
13
3
Hisao Imai1, Haruyasu Murakami1, Reiko Yoshino2, Akira Ono1, Hiroaki Akamatsu1, Tetsuhiko Taira1, Hirotsugu Kenmotsu1, Tateaki Naito1, Yoshio Tomizawa2, Toshiaki Takahashi1 1 Division of Thoracic Oncology, Shizuoka Cancer Center 2 Department of Respiratory Medicine, National Hospital Organization Nishigunma Hospital
abstracts
Background: Whether local treatment would be equally effective in non-small cell lung cancer patients with postoperative mediastinal lymph nodes recurrence (group A) and primary stage III disease (group B) remains unclear.
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v94/2240536 by guest on 24 October 2019
COMPARISON OF THE RADIOTHERAPEUTIC EFFICACY IN NSCLC WITH POSTOPERATIVE MEDIASTINAL LYMPH NODES RECURRENCE AND STAGE III
Methods: Between 2002 and 2009, in a total of 190 non-small cell lung cancer patients with mediastinal lymph nodes metastases treated by radiotherapy alone or chemoradiotherapy, the baseline patient characteristics, responses to radiotherapy alone or chemoradiotherapy and survival were compared between group A (n = 33) and group B (n = 157). Results: Male was the predominant gender, accounting for 60.6% of patients in group A and 78.9% of patients in group B (P = 0.04). Performance status (PS) 0 was the predominant PS, accounting for 78.7% of patients in group A and 57.3% of patients in group B (P = 0.02). The response rates in group A and group B were 66.6 and 72.3%, respectively (P = 0.64). PFS was not significant in group A and group B (median, 15.0 versus 11.0 months; hazard ratio, 0.78; 95% CI, 0.51–1.20; P = 0.26). Meanwhile, OS was superior in group A than in group B (median, 67.0 versus 39.0 months; hazard ratio, 0.56; 95% CI, 0.29–0.97; P = 0.03). Among postoperative patients, PFS (median, 12.5 versus 19.0 months; hazard ratio, 1.50; 95% CI, 0.64–3.49; P = 0.34) and OS (median, 67.0 versus 60.0 months; hazard ratio, 1.22; 95% CI, 0.36–4.14; P = 0.74) were no significance in radiotherapy alone group and chemoradiotherapy group, respectively. Conclusions: Postoperative mediastinal lymph nodes recurrent non-small cell lung cancer showed distinctive features: OS was superior in patients with postoperative mediastinal lymph nodes recurrence than in those with primary stage III disease, although the two groups showed comparable responses and PFS.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].